Management of Iron Supplements in Patients with Elevated Red Blood Cell Counts
Rationale for Discontinuing Iron Supplements
- The European Society for Parenteral and Enteral Nutrition (ESPEN) recommends reducing iron stores through venesection in conditions of iron overload to prevent complications 1
- Iron supplementation should be discontinued in patients with elevated red blood cell counts as this may indicate iron overload, which can lead to significant morbidity and mortality through organ damage 1
Assessment of Iron Status
- Before making decisions about iron supplementation, a comprehensive iron status evaluation should include serum ferritin as the primary marker of iron stores 2
- A complete blood count with RBC indices is necessary for assessing iron status 3
- High RBC count with elevated ferritin (>1000 ng/mL) strongly suggests iron overload requiring intervention 2
Management Algorithm
- For confirmed iron overload with high RBC, immediately discontinue all iron supplements and consider therapeutic phlebotomy if ferritin >1000 ng/mL 5, 6
- Avoid vitamin C supplements which can increase iron absorption and mobilization in patients with iron overload 6
Monitoring After Discontinuation
- Monitor hemoglobin and hematocrit regularly after stopping iron supplements, and check serum ferritin levels every 3 months until stabilized 2, 7
- Target ferritin level should be between 50-100 μg/L to prevent both iron overload and deficiency 6
Risks of Continued Iron Supplementation with High RBC
- Continued iron supplementation with elevated RBC can lead to cardiac dysrhythmias and cardiomyopathy 8
- Liver damage and potential cirrhosis can occur with continued iron supplementation in patients with high RBC 5
- Increased risk of infections, particularly from certain bacteria, is associated with iron overload 6
- Hyperviscosity syndrome with headaches and poor concentration can result from continued iron supplementation with high RBC 3
Special Considerations
- Patients with hereditary hemochromatosis require more aggressive management with regular therapeutic phlebotomy 9